Olympus October 2025 Urgent Field Safety Notice — What Olympus Finally Admitted About Its Duodenoscopes

The October 2025 UFSN was issued worldwide by Olympus between October 14 and 17, 2025, covering TJF-Q190V, TJF-Q290V, and TJF-Q170V duodenoscopes. Olympus admitted prior protocols were inadequate, naked-eye inspection was insufficient, and 10X magnification tools were required — confirming 2 deaths and 5 serious injuries.

The UFSN was issued simultaneously across multiple countries and was confirmed via the Estonian RAVIMIAMEET regulatory archive and the Health Products Regulatory Authority (HPRA) of Ireland. Olympus’s simultaneous worldwide issuance of the notice confirms the company was aware the problem was not isolated to a single market or facility — it was a global product-line issue affecting TJF-series duodenoscopes wherever they were in use.

The notice is significant not merely for what it confirms about the specific scopes covered, but for what it retroactively establishes about the protocols Olympus provided to hospitals for the full prior claims period. (Source: Olympus Urgent Field Safety Notice, October 14–17, 2025; confirmed via Estonian RAVIMIAMEET archive and HPRA Ireland.)

TJF-Q190V, TJF-Q290V, and TJF-Q170V — current-generation TJF-series duodenoscopes used in ERCP procedures at hospitals nationwide. These are not older recalled models but the current product line Olympus was actively selling and supporting as of October 2025.

The significance of the product line designation cannot be overstated. The October 2025 UFSN was not Olympus acknowledging a problem with a legacy device it had already taken off the market — it was Olympus acknowledging that its current-generation scopes, the ones actively in use in hospitals at the time of the notice, could not be adequately inspected using the protocols Olympus itself had prescribed for them. Olympus admitted that prior reprocessing protocols for all three models “required updates” because the prior instructions were inadequate.

Olympus’s October 2025 UFSN issued a new Visual Inspection Guide requiring 10X magnification tools to detect damage and contamination on TJF-series duodenoscopes that cannot be seen with the naked eye. If that contamination requires 10X magnification to detect in 2025, it was invisible to every hospital technician performing standard reprocessing before 2025.

The retroactive legal effect of this admission is direct. Every procedure performed with a TJF-Q190V, TJF-Q290V, or TJF-Q170V scope before October 2025 was performed using the pre-UFSN inspection protocol — which Olympus now admits was insufficient to detect the contamination and damage that required 10X magnification to identify. The inspection failure was systemic and continuous across the full pre-2025 claims period.

This is qualitatively different from prior FDA safety communications, which used uncertain language like “may be inadequate.” The October 2025 UFSN is Olympus’s own corporate admission — not a regulatory warning — that the protocols were, in fact, inadequate, and identifies specifically why: the visual inspection standard was insufficient without 10X magnification tools that Olympus never told hospitals to use.

The October 2025 UFSN confirmed 2 deaths and 5 serious injuries linked to TJF-series duodenoscopes at the time the notice was issued. These occurred from 2024 through the date of the notice, using current-generation scopes with protocols Olympus admits were inadequate.

These figures represent confirmed deaths and injuries from 2024 only — they do not include the historical toll from the 2012–2023 outbreak period, during which multiple hospital outbreaks documented additional fatalities linked to Olympus duodenoscopes. The Virginia Mason outbreak alone resulted in 16 deaths by March 2015, the UCLA outbreak resulted in 2 deaths, and the the Illinois teaching hospital outbreak involved 39 patients.

The UFSN death and injury count is an acknowledgment of the most recent period of confirmed harm; the full scope of harm attributable to Olympus’s inadequate protocols over the full claims period is the subject of ongoing litigation.

Yes. The admission that prior protocols were insufficient applies retroactively to all procedures performed with those protocols before the UFSN was issued. Every TJF-series ERCP before October 2025 used the protocols Olympus now admits were inadequate to detect contamination requiring 10X magnification.

Retroactivity here is not a legal theory requiring construction — it is the direct logical consequence of the admission. The UFSN states that the damage on TJF-series scopes requires 10X magnification to detect. That same damage was present in 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, and 2024. In all of those years, hospital staff were performing inspections without 10X magnification — because Olympus told them the naked-eye inspection was sufficient.

Olympus’s October 2025 admission that it was not sufficient applies to the full claims period. Patients who had ERCP procedures on or after January 1, 2015, using Olympus TJF-series scopes, and who developed confirmed infections requiring inpatient hospitalization and IV antibiotic treatment within 30 days, should contact Marin & Murphy for evaluation.

No. Olympus’s own UFSN confirms that prior protocols were presented to hospitals as adequate. Hospitals had no independent way to know the protocols were insufficient — Olympus alone controlled both what the protocols required and whether those protocols were adequate for the detection task.

This is the core of the product liability argument against Olympus rather than against the hospitals that performed ERCP procedures. The legal theory is that Olympus — not the hospital — was responsible for providing safe and adequate reprocessing instructions. Hospitals followed Olympus’s instructions. Olympus knew or should have known those instructions were inadequate — a conclusion supported by the decade of outbreak data, MDRs, warning letters, and criminal prosecution that preceded the October 2025 UFSN.

The UFSN is Olympus’s own admission that it failed to provide hospitals and patients with adequate safety information throughout the pre-October 2025 claims period. An 8-year retrospective study found that all manufacturer-recommended interventions for contamination control failed to produce a meaningful reduction in contamination rates — a result now explained by the UFSN’s admission that the inspection standard itself was insufficient.

(van der Ploeg K et al., Gut, 2024;73(4):613–621, PMID 38182137.)